Dihexa (also known as PNB 0408) is an experimental small molecule derived from angiotensin IV. It was engineered to cross the bloodbrain barrier and has shown synaptogenic effects in preclinical models. The often quoted What's happening with peptides right now is a major shift in how this space will be practiced. After a period of broad restriction, we're moving back toward substance specific evaluation and back into PEPTIDES ARE BACK! Following the withdrawal of nominations, the FDA will now remove 12 peptides from Category 2 and bring them before the Pharmacy Compounding Advisory Committee (PCAC) beginning July 23 24, 2026. Dihexa Research Grade Neurotrophic Molecule 20 mg PRG